Is there a role of everolimus or capecitabine and temozolomide in diffuse idiopathic pulmonary neuroendocrine cell hyperplasia in patients already on octreotide?

Topics: Thoracic Malignancies • Medical Oncology • Neuroendocrine Tumors • Pulmonology • Diffuse Parenchymal Lung Disease

Answer from: Medical Oncologist at Academic Institution

The key question is why there is a reason to change the treatment... Is it for worsening symptoms or progressive disease with overt lung NET development or progression of known lung NET?In a retrospective study of 55 patients with DIPNECH, only 18% had a progression to a lung NET (typical carcinoid)...

Related Questions